Characterization of interleukin 2-expanded human peripheral blood lymphocytes: Not only NKH-1+-NK cells but also NKH-1+ and NKH-1− T cells are LAK effectors

This publication has 42 references indexed in Scilit:

• A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone
  New England Journal of Medicine, 1987
• Interleukin 2 induces proliferation of normal “resting” human T cells in the absence of other known external stimulation
  Cellular Immunology, 1987
• Monoclonal antibodies against the NK cell-FcR and the T3-complex potentiate normal lymphocyte killing
  Cellular Immunology, 1986
• Recombinant interleukin-2-induced polyclonal proliferation of in vitro unstimulated human peripheral blood lymphocytes
  Cellular Immunology, 1986
• Monocyte‐dependent induction of proliferation of human peripheral T cells by recombinant interleukin 2
  European Journal of Immunology, 1986
• Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer
  New England Journal of Medicine, 1985
• Natural killer-mediated lysis of normal and malignant target cells, and its regulation by monocytes.
  The Journal of Experimental Medicine, 1985
• Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
  The Journal of Experimental Medicine, 1982
• Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.
  The Journal of Experimental Medicine, 1982
• Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows
  Science, 1976